Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension and chronic lung allograft dysfunction.
Rodatristat Ethyl- Altavant’s lead candidate rodatristat ethyl, is designed to block peripheral serotonin production and is in phase 2 development for the treatment of pulmonary arterial hypertension (NCT04712669). Rodatristat, delivered as a prodrug, is an orally bioavailable direct and reversible inhibitor of tryptophan hydroxylase. Preclinical studies provide evidence that treatment with rodatristat reduces the extent of vascular remodeling, and rodatristat was generally well tolerated and lowered serotonin production levels in healthy human subjects comparable to those associated with efficacy in preclinical studies.
Resources
More information on rodatristat’s mechanism of action
Altavant is now enrolling participants into our Phase 2B study for pulmonary arterial hypertension. For more information about the study please visit our ELEVATE study website
A Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension (ELEVATE 2)
Altavant Sciences News & Events
For more information, please contact:
Sidra M Hoffman, PhD
Director, Medical Science Liaison
Altavant Sciences
[email protected]
+1 (802)-989-3206